Growing Clinical Base NIMGenetics already serves over 50 diagnostic centers, clinics, and hospitals, indicating a solid foothold in the Spanish healthcare system. This diversified client base presents opportunities to expand into additional medical institutions and regional markets, especially by highlighting their high-resolution genomic diagnostic capabilities.

Innovation Collaboration The company's active collaboration with major industry players like Illumina and academic institutions opens avenues to co-develop advanced genomics solutions. Leveraging these associations can help target research institutions, laboratories, and biotech firms seeking cutting-edge diagnostic tools.

Expanding Service Offerings Recent launches, such as COVID-19 risk assessment via exome sequencing, showcase the company's ability to adapt quickly to emerging healthcare needs. Targeting organizations focused on infectious diseases and genetic risk prediction could unlock additional sales opportunities.

Funding & Growth Potential With a funding pool of 7.6 million dollars and revenues between one and ten million dollars, NIMGenetics is positioned for growth and investment. Sales strategies could focus on highlighting their innovative platform capabilities and potential for scaling genomic diagnostics across broader healthcare markets.

International Expansion The company’s recent strategic partnerships and participation in international events suggest a readiness to expand beyond Spain. Business development efforts could target markets with similar healthcare infrastructure, emphasizing their expertise in clinical genomics and personalized medicine solutions.